Sepsis - Diagnosis and Treatment Report

  • ID: 4380308
  • Report
  • Boston Strategic Partners
1 of 3
Real-World Patient Encounters and Reflects Real Physician Decisions and Encounter Characteristics in Key Areas

In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. Informed by real-world data from an Electronic Health Record (EHR) database of clinical and administrative records spanning 273 million encounters for 60 million patients in 600+ hospitals across the US, this report estimates 30% of all hospital discharges involve treatment of infectious organisms.

Sepsis is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we conduct an in-depth analysis of sepsis patient characteristics, medication management, costs, and laboratory testing.

Gram-positive bacteria are the likely causative agents of most sepsis infections. Physicians treat the vast majority of these infections with vancomycin, piperacillin-tazobactam, levofloxacin, and ceftriaxone. From 2010-2015, drug-resistant organisms caused an astonishing 40% of bacterial sepsis infections. After confirmatory diagnosis, over half of sepsis patients undergo a change in antibiotic therapy.

This report provides quantitative, objective data using real-world patient encounters and reflects real physician decisions and encounter characteristics (e.g. patient response to therapy and outcomes) in key areas, such as antibiotic resistant pathogens and antimicrobial stewardship.

Note: Product cover images may vary from those shown
2 of 3

1. Outline

2. Executive Summary

3. Incidence and Impact of Disease

  • Incidence
  • Length of Stay
  • Total Cost

4. Patient Demographics

  • Age
  • Insurance type
  • Gender
  • Region
  • Mortality
  • Comorbid Conditions

5. Patient Segmentation by Diagnostic Testing
Causative Etiologic Agent

6. Length of Stay and Cost by Patient Segment

  • Age at Admission
  • APACHE II Score
  • First Care Setting

7. Patient Flow through the Hospital

  • Admission Site
  • Lab Testing
  • Lab TAT
  • Results
  • Etiology
  • Empiric Therapy
  • Change in treatment

8. Drug Share for Key Therapeutics

  • Most Common
  • LOS
  • APACHE Score
  • Treatment Duration
  • Product Dashboards
    • Market Share
    • Demographics
    • Hospitalization

9. Outcomes of Treatment

  • Antibiotic Usage
  • Mortality
  • Cost per Patient

10. Drug Resistant Sepsis

  • Current Trends
  • Costs
  • Comorbidity
  • LOS
  • Mortality

11. Database Overview

12. Methodology

Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown